Specific recognition lamivudine-resistant HIV-1 by cytotoxic T lymphocytes

AIDS

Volumn 14, Issue 6, 2000, Pages 653-658

  Schmitt, Matthias ^a   Harrer, Ellen ^a   Goldwich, Andreas ^a   Bäuerle, Michael ^a   Graedner, Irina ^a   Kalden, Joachim R ^a   Harrer, Thomas ^a,b  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b Department of Medicine III ^*  (Germany)

Author keywords

3TC; CTL; Cytotoxic T lymphocytes; Drug resistance; HIV 1; Lamivudine; Reverse transciptase mutation

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; CHROMIUM; DIDANOSINE; EPITOPE; HLA A2 ANTIGEN; LAMIVUDINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE; SAQUINAVIR; STAVUDINE; SYNTHETIC PEPTIDE; VIRUS PROTEIN; ZIDOVUDINE;

ADULT; ARTICLE; CELL STIMULATION; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FEMALE; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE CLONE; MALE; MOLECULAR RECOGNITION; MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN VARIANT; RADIOIMMUNOASSAY;

ADULT; ANTI-HIV AGENTS; CELL LINE; CYTOTOXICITY, IMMUNOLOGIC; DRUG RESISTANCE, MICROBIAL; DRUG THERAPY, COMBINATION; EPITOPES, T-LYMPHOCYTE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HLA-A2 ANTIGEN; HUMANS; LAMIVUDINE; LYMPHOCYTE ACTIVATION; MALE; MUTATION; REVERSE TRANSCRIPTASE INHIBITORS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0034054388     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200004140-00004     Document Type: Article

References (19)

1. 1. Schuurman R, Nijhuis M, van Leeuwen R et al. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J Infect Dis 1995, 171:1411-1419.
2. 2. Wainberg MA, Salomon H, Gu Z et al. Development of HIV-1 resistance to (-) 2′-deoxy-3′-thiacytidine in patients with AIDS or advanced AIDS-related complex. AIDS 1995, 9:351-357.
3. 3. Tisdale M, Kemp SD, Parry NR, Larder BA. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc Natl Acad Sci USA 1993, 90:5653-5656.
4. 4. Larder BA, Purifoy DJM, Powell KL, Darby G. Site-specific muta-genesis of AIDS virus reverse transcriptase. Nature 1987, 327:716-717.
5. 5. Tisdale M, Alnadaf T, Cousens D. Combination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89. Antimicrob Agents Chemother 1997, 41:1094-1118.
6. 6. Gao Q, Gu Z, Hiscott J, Dionne G, Wainberg MA. Generation of drug-resistant variants of human immunodeficiency virus type 1 by in vitro passage in increasing concentrations of 2′,3′-dideoxycytidine and 2′,3′-dideoxy-3′-thiacytidine. Antimicrob Agents Chemother 1993, 37:130-133.
7. 7. Boucher CA, Cammack N, Schipper P et al. High-level resistance to (-) enantiomeric 2′-deoxy-3′-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 1993, 37:2231-2234.
8. 8. Back NK, Nijhuis M, Keulen W et al. Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme. EMBO J 1996, 15:4040-4049.
9. 9. Wainberg MA, Drosopoulos WC, Salomon H et al. Enhanced fidelity of 3TC-selected mutant HIV-1 reverse transcriptase. Science 1996, 271:1282-1285.
10. 10. Harrer E, Harrer T, Barbosa P et al. Recognition of the highly conserved YMDD region in the human immunodeficiency virus type 1 reverse transcriptase by HLA-A2-restricted cytotoxic T lymphocytes from an asymptomatic long-term nonprogressor. J Infect Dis 1996, 173:476-479.
11. 11. Walker BD, Flexner C, Birch-Limberger K et al. Long-term culture and fine specificity of human cytotoxic T-lymphocyte clones reactive with human immunodeficiency virus type. Proc Natl Acad Sci USA 1989, 86:9514-9518.
12. 12. Harrer T, Harrer E, Barbosa P et al. Recognition of two overlapping CTL epitopes in HIV-1 p17 by CTL from a long-term nonprogressing HIV-1-infected individual. J Immunol 1998, 161:4875-4881.
13. 13. Mayers DL. Prevalence and incidence of resistance to zidovudine and other antiretroviral drugs. Am J Med 1997, 102:70-75.
14. 14. Hecht FM, Grant RM, Petropoulos CJ et al. Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors. N Engl J Med 1998, 339:307-311.
15. 15. Iversen AK, Shafer RW, Wehrly K et al. Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy. J Virol 1996, 70:1086-1090.
16. 16. van der Burg SH, Klein MR, Pontesilli O et al. HIV-1 reverse transcriptase-specific CTL against conserved epitopes do not protect against progression to AIDS. J Immunol 1997, 159:3648-3654.
17. 17. Brander C, Hartman KE, Trocha AK et al. Lack of strong immune selection pressure by the immunodominant, HLA-A*0201-restricted cytotoxic T lymphocyte response in chronic human immunodeficiency virus-1 infection. J Clin Invest 1998, 101:2559-2566.
18. 18. Haas G, Samri A, Gomard E et al. Cytotoxic T-cell responses to HIV-1 reverse transcriptase, integrase and protease. AIDS 1998, 12:1427-1436.
19. 19. Douek DC, McFarland RD, Keiser PH et al. Changes in thymic function with age and during the treatment of HIV infection. Nature 1998, 396:690-695.